Department of Radiation Oncology, Freiburg University, Freiburg, Germany.
Curr Oncol Rep. 2013 Apr;15(2):162-9. doi: 10.1007/s11912-012-0291-3.
Although neoadjuvant chemoradiotherapy has been tested for more than two decades and can be safely delivered to patients with non-metastatic pancreatic cancer, no randomised trials have been reported until now. Here we provide an overview of the first randomised trial in patients with potentially resectable cancer and of the latest developments in neoadjuvant therapy for this group of patients. It is necessary to continue to perform clinical trials in this field to accurately identify the effect on survival and quality of life in patients with potentially resectable, borderline resectable and unresectable pancreatic cancer. Aspects of imaging for restaging and clinical prognostic factors are also discussed given they will be useful instruments for future trials.
尽管新辅助放化疗已经进行了二十多年的测试，并且可以安全地用于治疗非转移性胰腺癌患者，但直到现在还没有报告随机试验。在这里，我们提供了首个针对潜在可切除癌症患者的随机试验概述，以及该组患者新辅助治疗的最新进展。有必要在该领域继续进行临床试验，以准确确定对潜在可切除、边界可切除和不可切除胰腺癌患者的生存和生活质量的影响。鉴于影像学再分期和临床预后因素将是未来试验的有用工具，因此也讨论了它们的相关内容。
